7,588
Views
74
CrossRef citations to date
0
Altmetric
Editorial

Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)

, , , , , , & show all
Pages 973-977 | Received 08 Mar 2016, Accepted 19 May 2016, Published online: 06 Jul 2016

References

  • Dömling A, Holak TA. Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed. 2014;53:2286–2288.
  • Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
  • Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350–354.
  • Carvalho S, Levi-Schaffer F, Sela M, et al. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR review X. Br J Pharmacol. 2016;173:1407–1424.
  • Wolchok JD. PD-1 blockers. Cell. 2015;162:937.
  • Zak KM, Radoslaw K, Sara P, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23:2341–2348.
  • President and Fellows of Harvard College. Modulators of immunoinhibitory receptor PD-1, and methods of use thereof. WO2011/082400 A3 2011.
  • Bristol-Myers Squibb Company. Compounds useful as immunomodulators. WO2015/034820 A1. 2015.
  • Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7:30323–30335.
  • Hanley RP, Horvath S, An J, et al. Salicylates are interference compounds in TR-FRET assays. Bioorg Med Chem Lett. 2016;26:973–977.
  • Aurigene Discovery Technologies Limited. 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators. WO2015/033301 A1. 2015.
  • Chang H-N, Liu B-Y, Qi Y-K, et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew Chem Int Ed. 2015;54:11760–11764.
  • Aurigene Discovery Technologies Limited. Immunosuppression modulating compounds. US2011/0318373 A3. 2011.
  • Mautea RL, Gordona SR, Mayere AT, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. PNAS. 2015;112:6506–6514.
  • Baruch K, Deczkowska A, Rosenzweig N, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat Med. 2016;22:135–137.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.